eligibility_summary
Includes: women 18–75 with HER2‑negative advanced breast cancer, ECOG 0–1, 1–2 prior lines (CDK4/6 if HR+), measurable disease (RECIST v1.1), asymptomatic or treated/stable brain mets, no prior PD‑(L)1, life expectancy ≥6 mo, adequate organs. Excludes: active brain mets, prior anti‑HER2/TROP‑2/topo‑ADC, uncontrolled effusions, recent therapy, autoimmune disease or immunosuppression, active HBV/HCV/cirrhosis/infection, uncontrolled CV disease, live vaccine <4 wks, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, parallel-arm trial in HER2‑negative advanced breast cancer testing two antibody–drug conjugates (ADCs) with a PD‑L1 inhibitor. Arms: SHR‑A1811 + adebrelimab and SHR‑A1921 + adebrelimab (IV). Drug types and mechanisms: • Adebrelimab: human monoclonal IgG1 antibody that blocks PD‑L1 (immune checkpoint inhibitor), preventing PD‑1 engagement and restoring cytotoxic T‑cell activity. • SHR‑A1811 and SHR‑A1921: novel ADCs (antibody linked to a cytotoxic payload), the listing does not specify their target antigen(s) or payloads. ADCs bind a tumor cell‑surface antigen, are internalized, and release an intracellular toxin to kill antigen‑expressing cells. Targeted cells/pathways: • Antigen‑positive HER2‑negative breast cancer cells via ADC‑mediated cytotoxicity. • PD‑1/PD‑L1 immune checkpoint on tumor/immune cells to enhance T‑cell–mediated antitumor responses.